Amneal Pharmaceuticals, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 6, 2020 and accepted by EDGAR at Aug 6, 2020, 16:22 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-04-01 to 2020-06-30 | $464.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months2020-01-01 to 2020-06-30 | $963.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2020-04-01 to 2020-06-30 | $319.7m | us-gaap:CostOfGoodsAndServicesSold |
| Cost of revenue | 6 months2020-01-01 to 2020-06-30 | $633.2m | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-04-01 to 2020-06-30 | $144.2m | us-gaap:GrossProfit |
| Gross profit | 6 months2020-01-01 to 2020-06-30 | $327.7m | us-gaap:GrossProfit |
| Research and development | 3 months2020-04-01 to 2020-06-30 | $45.6m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $82.0m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2020-04-01 to 2020-06-30 | $80.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months2020-01-01 to 2020-06-30 | $158.9m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | $10.8m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | $68.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2020-04-01 to 2020-06-30 | $2.2m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | −$106.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$12.0m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | $103.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | −$0.08 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | $0.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-04-01 to 2020-06-30 | −$0.08 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months2020-01-01 to 2020-06-30 | $0.70 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2020-04-01 to 2020-06-30 | 147,392,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months2020-01-01 to 2020-06-30 | 148,309,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | $228.3m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $15.9m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $266.1m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $1.48bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $4.06bn | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $655.0m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2020-06-30 | $2.76bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-06-30 | $29.8m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2020-06-30 | $306.0m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001723128-20-000013. Last ingested by Listed: Nov 10, 2026, 02:45 ET. Listed shows no prices and gives no investment advice.